The role of signaling pathways in the development and treatment of hepatocellular carcinoma (Q37773788)

22 August 2017

1 reference

title

The role of signaling pathways in the development and treatment of hepatocellular carcinoma (English)

1 reference

22 August 2017

1

1 reference

22 August 2017

2

1 reference

22 August 2017

A X Zhu

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

19 July 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

29

1 reference

22 August 2017

issue

36

1 reference

22 August 2017

page(s)

4989-5005

1 reference

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Fratricidal retroviruses: a new twist in gene therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

New therapies for hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

c-met mRNA overexpression in human hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Primary liver cancer: worldwide incidence and trends

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Review article: steatosis, the metabolic syndrome and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

BAY 43-9006 inhibition of oncogenic RET mutants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Sunitinib: from rational design to clinical efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Regulation of Raf-1 by direct feedback phosphorylation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Targeting RAS signalling pathways in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Early molecular and genetic determinants of primary liver malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Fundamental Concepts of the Angiogenic Process

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

FOXO transcription factors at the interface between longevity and tumor suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Regulation of phospholipase C isozymes by ras superfamily GTPases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Raf kinases: function, regulation and role in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Sorafenib in advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Requirement of Ras-GTP-Raf Complexes for Activation of Raf-1 by Protein Kinase C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Emerging multipotent aspects of hepatocyte growth factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Induction of the estrogen receptor by ablation of DNMT1 in ER-negative breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Management of hepatocellular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Mechanisms of normal and tumor-derived angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Global cancer statistics, 2002

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Insulin-like growth factors and neoplasia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Bone marrow stromal cells as a genetic platform for systemic delivery of therapeutic proteins in vivo: human factor IX model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Hepatocellular carcinoma: molecular pathways and new therapeutic targets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Emerging drugs for hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

mTOR and P70 S6 kinase expression in primary liver neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Phosphorylation of hippocampal Erk-1/2, Elk-1, and p90-Rsk-1 during contextual fear conditioning: interactions between Erk-1/2 and Elk-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Cell signaling by receptor tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Analysis of the transcriptional program induced by Raf in epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Angiogenesis and hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Expression of the c-met protooncogene in human hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Opportunities for targeted therapies in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Molecular pathogenesis of human hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Crosstalk between Pten and Ras signaling pathways in tumor development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Pivotal role of mTOR signaling in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Genomics and signaling pathways in hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Molecular pathogenesis of human hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Molecular mechanisms involved in macrophage survival, proliferation, activation or apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Expression of vascular endothelial growth factor in human hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.236

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.236

1 reference

22 August 2017

1 reference